Related Experiment Video
Updated: Jan 21, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Strategies to Overcome Residual Risk During Statins Era
Kyoung Im Cho1, Jongwook Yu2, Toshio Hayashi3
1Department of Cardiology, Kosin University Gospel Hospital.
Insights
Atherosclerosis management faces residual cardiovascular risk despite statin therapy. This review explores residual cholesterol and inflammation as key factors and proposes strategies to mitigate these risks in the statin era.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Pharmacology
Background:
- Atherosclerosis is a major medical concern, linked to cardiovascular and endocrine disorders.
- Low-density lipoprotein cholesterol (LDL-C) is a key risk factor for atherosclerosis.
- Statins effectively lower LDL-C and improve cardiovascular outcomes, but residual risk remains.
Purpose of the Study:
- To review the concept of residual risk in atherosclerosis management.
- To discuss the roles of residual cholesterol and inflammation in cardiovascular events.
- To propose strategies for overcoming residual risk in the era of statin therapy.
Main Methods:
- Literature review of recent studies on atherosclerosis, statins, and residual risk.
- Analysis of the impact of residual cholesterol and inflammation on cardiovascular events.
- Synthesis of current evidence to suggest management strategies.
Main Results:
- Intense statin therapy does not eliminate cardiovascular risk in all patients.
- Residual cholesterol and inflammation are implicated as significant contributors to residual cardiovascular risk.
- Current management strategies may not fully address these residual risk factors.
Conclusions:
- Residual risk remains a critical challenge in managing patients with atherosclerosis on statin therapy.
- Targeting residual cholesterol and inflammation is essential for comprehensive cardiovascular risk reduction.
- Novel therapeutic strategies are needed to effectively manage residual risk and improve patient outcomes.
Abstract:
At present, atherosclerosis is one of the most important field in clinical and research medicine. Because it is closely related to cardiovascular (CV) and endocrine disorders such as coronary artery disease, cardiometabolic disorders, much research on how to manage atherosclerosis has been performed. The low-density lipoprotein cholesterol (LDL-C) concentration has been established as an independent risk factor for developing atherosclerosis, and considerable effort has been committed to educating both physicians and the general public on the importance of lowering LDL-C with statins. Although statins have already significantly improved CV outcomes, patients with LDL-C target levels achieved by intense statin therapy still have significant remaining CV risk. Statins already play a central role in managing hyperlipidemia; however, residual risk with statins is an important field of managing remaining CV risk. Recent studies have suggested residual cholesterol and inflammation risks in causing CV events. In the current review, we will discuss residual risk and suggest strategies to overcome it in the statins era.
More Related Videos
10:31Residue-Specific Exchange of Proline by Proline Analogs in Fluorescent Proteins: How "Molecular Surgery" of the Backbone Affects Folding and Stability
Published on: February 3, 2022
04:57Residue-Free Fabrication of van der Waals Heterostructures of Two-Dimensional Materials
Published on: July 18, 2025
Related Concept Videos
Residual Stresses
Residual Plots
When the residual values are plotted against the variable x, it is called a residual...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Residual Stresses in Circular Shafts
Relative Risk
Residual Stresses in Bending